BMY Q3 2026 Earnings Analysis
Bristol-Myers reported 7% Q3 revenue growth to $13.1B, growth portfolio +12% to $7.7B, announced positive late-stage pipeline results, and raised full-year EPS guidance to $6.35-$6.55.
Key Metrics
Key Takeaways
- Growth portfolio revenue rose 12% to $7.7B with 8 medicines annualizing over $1B, driving sustained expansion.
- Four registrational studies read out positively including Symvexis, admilparant IPF, RAISE-101, and Arlocelll.
- Full-year 2026 EPS guidance raised to $6.35-$6.55 despite upcoming LOE impacts in legacy portfolio.
Listen On
Available In
Transcript
// Full episode scriptWelcome to Beta Finch, your AI-powered earnings breakdown where we turn dense earnings calls into conversations you'd actually want to listen to. I'm Alex.
And I'm Jordan. Today we're digging into Bristol Myers Squibb's third quarter 2026 results, reported this past Thursday.
Before we get into it, our standard disclaimer: this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.
Right, let's get into the numbers because honestly, Alex, this was a pretty strong quarter for BMS.
It was. Total revenue came in at $13.1 billion, up 7% year-over-year. But the number that really matters is the growth portfolio — that's their newer, patent-protected medicines — which jumped 12% to $7.7 billion.
And that's the story investors want to hear with Bristol, right? They've got this massive legacy portfolio dealing with patent cliffs, but the growth portfolio is now carrying real weight. Eight products are annualizing over a billion dollars each. That's a surprisingly diversified base.
Diversified is the key word. Reblozyl grew 22% to $750 million, Breyanzi — their CAR-T therapy — grew 48% to $526 million. Camzyos jumped 42%. These aren't just incremental wins.
The one that caught my eye is Qvantig, the subcutaneous version of Opdivo. Sequential growth of 28%, now annualizing over $1.3 billion. They've converted about 17% of their IV Opdivo business to this subcutaneous form, and management said they're tracking toward the higher end of their 30-40% conversion target.
Which matters because Opdivo itself actually declined 6% as patients shift over — but that's by design. It's essentially the same revenue moving to a better-margin, more convenient format. A three-minute in-office injection instead of an infusion.
Meanwhile, Eliquis — still their biggest legacy product — grew 26% to $4.7 billion. Management flagged that Q4 will see some impact from loss of exclusivity in Europe, and there's a bigger $1.5 to $2 billion step-down expected in 2027. So enjoy this number while it lasts.
On the bottom line, diluted EPS was $1.35, though that includes a $0.58 hit from acquired IP R&D charges and licensing income. Strip that out, and the underlying EPS story actually improved by about 15 cents versus their prior guide.
And they raised full-year guidance — new EPS range of $6.35 to $6.55. Gross margin held around 68.4%, and they're sitting on $13 billion in cash with $4.2 billion in operating cash flow this quarter alone. That's a company with real flexibility.
Let's talk pipeline, because this quarter was genuinely eventful. Bristol got FDA approval for Symvexis, their first CELMoD — that's a targeted protein degradation drug — for multiple myeloma. Early launch feedback has been positive.
And it wasn't just one win. In the span of about two months, they had four positive registrational readouts. Admilparant hit its primary endpoint in a Phase 3 pulmonary fibrosis trial. Their radiopharmaceutical RYZ101 showed meaningful progression-free survival improvement in a rare tumor type called GEP-NETs. And Arlocel, their CAR-T for multiple myeloma, delivered positive Phase 2 results.
CEO Christopher Boerner was clearly feeling good about this streak, calling it a "next wave of launches coming into sharper focus." They're even putting real money behind it — $2.3 billion for a new manufacturing campus in Houston, plus $170 million for a radiopharmaceutical facility in Indiana.
Now, the Q&A had some interesting tension. On admilparant, an analyst pushed on why the higher 120-milligram dose showed improvement but didn't hit statistical significance. The chief medical officer, Cristian Massacesi, was pretty transparent — said they're still digging into the data and will present more at a medical meeting next year. It's not a disaster, but it's a asterisk worth watching.
There was also a tougher moment around their autoimmune CAR-T program, Zolacel. A patient death from sepsis pneumonia came up, tied to a voluntary clinical pause from earlier this year. Management said it was an isolated case out of 190 patients treated, and they believe they've identified and fixed the manufacturing root cause. Boerner personally jumped in to defend the program's long-term potential.
And then there's Cobenfy, their schizophrenia drug — growth was only 33% to $57 million, which sounds decent but is modest relative to the hype this drug once had. Management admitted physicians are struggling with dosing titration and managing nausea side effects. They're pinning hopes on a much bigger opportunity: expanding into Alzheimer's-related psychosis, a market with zero approved treatments today.
So what does this all mean for investors going forward? The near-term story is solid execution — growth portfolio offsetting legacy declines, guidance raised, strong cash generation.
But the real debate is 2027 and beyond. You've got the Eliquis cliff coming, you've got several binary pipeline readouts — Milvexian in stroke prevention and atrial fibrillation, Sotyktu in lupus, more Cobenfy data — all landing over the next year. Management kept emphasizing financial discipline and business development optionality, which tells me they're very aware the market wants proof they can bridge that gap.
Before we wrap, Jordan, want to hit our closing disclaimer?
Of course. Everything discussed is AI-generated analysis for educational purposes. Past performance doesn't guarantee future results. Please do your own due diligence.
Bottom line: Bristol Myers had a genuinely productive quarter — numbers beat, pipeline delivered, guidance moved up. The next twelve months are shaping up to be pivotal as several of these pipeline bets either pay off or don't.
We'll be watching those Milvexian and Sotyktu readouts closely before year-end, plus how the Symvexis launch trajectory holds up into 2027.
That's it for this episode of Beta Finch. Thanks for listening, and we'll catch you next time.
See you then.